Schering-Plough

Worldwide Prescription Products

Schering-Plough Corporation
2000 Galloping Hill Road Kenilworth, NJ
07033-0530

June 2008

Phase II (New Entities)

Adenosine 2a Receptor Antagonist
Parkinson's Disease

AMPAkine
Depression

Boceprevir*
Hepatitis C

CXCR2 Receptor Antagonist
COPD

Glycine Uptake Inhibitor
Schizophrenia

Pleconaril
Common Cold and Asthma Exacerbations

QAB/Mometasone Combination
Asthma
COPD

Rolapitant
Emesis

Sublingual Tablet-Based Immunotherapy[3]
Dust Mite Allergies
Ragweed Allergies

Topical Antifungal
Onychomycosis

Phase II (Value Adding Projects)

NOXAFIL
I.V. Formulation

TEMODAR
Brain Metastases
Variety of Solid Tumors

Phase III (New Entities)

Acadesine
Ischemia-Reperfusion Injury

Corifollitropin alfa
Controlled Ovarian Stimulation

Esmirtazapine
Insomnia
Hot Flashes

Golimumab (CNTO 148)[1]
Ulcerative Colitis

Mometasone/Formoterol Combination
Asthma
COPD

NOMAC/E_2
Contraceptive

Sublingual Tablet-Based Immunotherapy[3]
Grass Pollen Allergies

Thrombin Receptor Antagonist
Acute Coronary Syndrome
Secondary Prevention

Vicriviroc
HIV Infection

Phase III (Value Adding Projects)

INTEGRILIN
Early Acute Coronary Syndrome

NASONEX
Rhinosinusitis

TEMODAR
Metastatic Melanoma

VYTORIN[2] - Outcomes Trials
SEAS - Aortic Stenosis
SHARP - Renal Disease
IMPROVE-IT - Acute Coronary Syndrome

Regulatory Application Filed (New Entities)

Asenapine
Schizophrenia (U.S.)
Bipolar Mania Disorder (U.S.)

CLARITIN/Singulair[2]
Seasonal Allergic Rhinitis (U.S.)

▶ **Golimumab (CNTO 148)[1]**
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis

Sugammadex
Anesthesia (U.S., EU, Japan)

Regulatory Application Filed (Value Adding Projects)

ASMANEX
Asthma (Japan)

NASONEX
Allergic Rhinitis (Japan)

NOXAFIL
Serious Fungal Infections (U.S.)

PEGINTRON
Malignant Melanoma (U.S., EU)

REMERON
Anti-depressant (Japan)

TEMODAR
I.V. Formulation (U.S., EU)

ZETIA[2]
Pediatric Primary Hypercholesterolemia (U.S.)

Investor Contacts:

Janet Barth (908) 298-7011
Joe Romanelli (908) 298-7904

The SGP Product Pipeline is solely intended to provide to investors general information regarding Schering-Plough projects in development and, for this reason, the information is not represented to be complete. Due to market factors and the nature of the development and approval process, the information - including the status of these projects - is subject to change. The Pipeline speaks only to the date hereof. Schering-Plough does not assume any duty to update this information.

"International Status" does not necessarily imply that the company will be marketing the compound in all major countries.

▶ Phase advance
▶ Indication advance
[1] International rights only
[2] J.V. with Merck
[3] North American rights only
* Boceprevir will remain in Phase II until patient dosing commences in the Phase III trial.

ProductPipeline

Schering-Plough

Worldwide Prescription Products

Schering-Plough Corporation
2000 Galloping Hill Road Kenilworth, NJ
07033-0530

June 2008

Phase II

The following Phase II projects from the Organon Biosciences acquisition have been added to the SGP Product Pipeline: **AMPAkine** *for the treatment of depression and* **Glycine Uptake Inhibitor** *for the treatment of schizophrenia.*

The following Phase II projects are no longer being pursued and therefore, have been removed from the SGP Product Pipeline: **ASENTAR** *for prostate cancer;* **PDE 5 Inhibitor** *for erectile dysfunction; and* **SARASAR** *for myelodyplastic syndrome, breast cancer and a variety of solid tumors.*

Boceprevir

In May 2008, Schering-Plough announced that it is initiating two Phase III studies with boceprevir in patients chronically infected with hepatitis C virus (HCV) genotype 1. The compound will remain in Phase II until patient dosing commences in the Phase III trial.

Sublingual Tablet-Based Immunotherapy[3]

Two new indications have been added to Phase II for the treatment of dust mite and ragweed allergies, as part of the development agreement with ALK-Abello.

Regulatory Application Filed

CLARITIN/Singulair[2]

In April 2008, the Schering-Plough/MERCK Pharmaceuticals joint venture received a not-approvable letter from the Food and Drug Administration (FDA) for the proposed fixed combination of loratadine/montelukast. Schering-Plough/MERCK Pharmaceuticals is evaluating the agency's response.

Golimumab[1]

In March 2008, Centocor and Schering-Plough filed a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting the approval of golimumab as a monthly subcutaneous treatment for adults with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

PEGINTRON

Schering-Plough announced the acceptance by the FDA of the New Drug Application filing for PEGINTRON for the treatment of malignant melanoma. This application was given priority review status. In March 2008, the FDA issued a complete response and asked the Company to provide additional data to support the application.

Sugammadex

In June 2008, Schering-Plough reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of sugammadex for routine reversal of the muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age).

Current Approvals

REBETOL

Approved in the US in March 2008 for weight-based dosing of REBETOL (800-1400 mg daily) as part of a combination therapy of PEGINTRON and REBETOL for chronic hepatitis C. The revised label also recommends a shorter, 24-week course of the combination therapy for patients with chronic hepatitis C virus (HCV) genotype 2 or 3.

REMICADE[1]

Approved in the EU in April 2008 for demonstrating a reduction of ulcerative colitis related hospitalizations and surgical procedures.

Approvals

ASMANEX (DPI)
Pediatric Asthma [U.S. 2/08]

CAELYX[1]
Multiple Myeloma [EU 11/07]

CLARINEX-D 12 Hour
Allergic Rhinitis with Congestion [U.S. 2/06]

NASONEX
Unscented [EU 4/07]

NOXAFIL
Oropharyngeal Candidiasis (OPC) [U.S. 10/06, EU 11/06]
Prevention of Invasive Fungal Infections [U.S. 9/06, EU 11/06]

PEGINTRON/REBETOL
Weight-Based Dosing [U.S. 3/08]
HCV / HIV coinfection [EU 6/07]

REMICADE[1]
Reduction of Ulcerative Colitis surgical procedures [EU 4/08]
Pediatric Crohn's Disease [EU 3/07]
Second-line Crohn's Disease [EU 10/06]
Psoriatic Arthritis Monotherapy [EU 3/06]

TEMODAR
Astrocytoma / Glioblastoma Multiforme [Japan 7/06]

VYTORIN[2]
Rosuvastatin data / labeling [U.S.10/06]
Atorvastatin data / labeling [U.S. 3/06]

ZETIA[2]
Lipid Lowering Monotherapy [Japan 4/07]

[1]International rights only [2]J.V. with Merck [3]North American rights only

PipelineUpdate